India, Oct. 30 -- Kiniksa Pharmaceuticals International plc (KNSA) has turned lead drug ARCALYST's strong sales growth into a compelling stock story, with shares delivering more than a 120% gain year-to-date as the drug moves closer to blockbuster status.
This biopharmaceutical company is developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its lead drug ARCALYST is an interleukin-1 inhibitor indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older; for maintenance of remission of Deficiency of Interleukin-1 Receptor Ant...